Clinical Trial

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

Name: To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors — clinical trial record (NCT06948539)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

To explore the tolerability and pharmacokinetics of TQB2101 for injection in subjects with advanced malignant tumors.

Trial Details

NCT Number	NCT06948539
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions	Breast Cancer, Lung Cancer, Colorectal Cancer
Enrollment	66 participants
Start Date	2025-04
Primary Completion	2026-10 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2025-04-29